Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Introduction: a fresh look at monoamine oxidase inhibitors for depression.

Cohen LJ, Sclar DA.

J Clin Psychiatry. 2012;73 Suppl 1:3-4. doi: 10.4088/JCP.11096su1c.00. No abstract available.

2.

Discussion: a fresh look at monoamine oxidase inhibitors for depression.

Cohen LJ, Sclar DA, Culpepper L, Flockhart DA, Hirschfeld RM, Thase ME, VanDenBerg CM.

J Clin Psychiatry. 2012;73 Suppl 1:42-5. doi: 10.4088/JCP.11096su1c.07. No abstract available.

3.

[MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].

Köhler S, Stöver LA, Bschor T.

Fortschr Neurol Psychiatr. 2014 Apr;82(4):228-36; quiz 237-8. doi: 10.1055/s-0034-1365945. Epub 2014 Apr 7. Review. German. No abstract available.

PMID:
24710679
4.

Atypical depression. A valid clinical entity?

Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM.

Psychiatr Clin North Am. 1993 Sep;16(3):479-95. Review.

PMID:
8415233
5.

[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].

Volz HP, Gleiter CH, Möller HJ.

Nervenarzt. 1996 May;67(5):339-47. Review. German.

PMID:
9005342
6.

Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.

Flockhart DA.

J Clin Psychiatry. 2012;73 Suppl 1:17-24. doi: 10.4088/JCP.11096su1c.03. Review.

7.

Drugs for depression.

[No authors listed]

Med Lett Drugs Ther. 2016 Jul 4;58(1498):85-90. No abstract available.

PMID:
27348144
8.
9.

N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.

Carvalho AF, Macêdo DS, Goulia P, Hyphantis TN.

J Clin Psychopharmacol. 2013 Oct;33(5):719-20. doi: 10.1097/JCP.0b013e31829839c6. No abstract available.

PMID:
23899640
10.

The use of monoamine oxidase inhibitors in primary care.

Culpepper L.

J Clin Psychiatry. 2012;73 Suppl 1:37-41. doi: 10.4088/JCP.11096su1c.06. Review.

11.

Depression in medical illness. Workshop report.

Paykel E.

Int Clin Psychopharmacol. 1993 Jan;7(3-4):205-7. No abstract available.

PMID:
8468445
12.

Antidepressants: which to use first?

Lam RW.

Can J Psychiatry. 1992 Oct;37(8):592-3. No abstract available.

PMID:
1423167
13.

The pharmacological management of depression.

Murphy S, Tyrer P.

Int Rehabil Med. 1984;6(2):vi-viii. No abstract available.

PMID:
6746200
14.

[Moclobemide].

Gleiter C, Volz HP.

Dtsch Med Wochenschr. 1995 Aug 25;120(34-35):1175-6. German. No abstract available.

PMID:
7656852
15.

Endogenous depression: biochemical determinants and drug treatment.

Hollister LE.

Drug Ther. 1982:81-98. Review. No abstract available.

PMID:
7049653
16.

Reversible monoamine oxidase-A inhibitors in resistant major depression.

Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.

Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Review.

PMID:
8313400
17.

Monoamine oxidase inhibitors revisited: what you should know.

Goldberg JF, Thase ME.

J Clin Psychiatry. 2013 Feb;74(2):189-91. doi: 10.4088/JCP.12ac08299. No abstract available.

PMID:
23473352
18.

[Atypical depression: evolution toward a specific pharmacologic and efficacious treatment?].

Dassylva B, Fontaine R.

Can J Psychiatry. 1995 Mar;40(2):102-8. Review. French.

PMID:
7788612
19.
20.

Results of the STAR*D study: implications for clinicians and drug developers.

Preskorn SH.

J Psychiatr Pract. 2009 Jan;15(1):45-9. doi: 10.1097/01.pra.0000344918.51404.1e. No abstract available.

PMID:
19182564

Supplemental Content

Support Center